Mortality Benefit of Recombinant Human Interleukin-1 Receptor Antagonist for Sepsis Varies by Initial Interleukin-1 Receptor Antagonist Plasma Concentration*Nuala J. Meyer, Steven M. Opal, John P. Reilly et al.|Critical Care Medicine|2017Cited by 98
Identification of Distinct Clinical Subphenotypes in Critically Ill Patients With COVID-19Charles R. Vasquez, Steven G. Coca, Jesse Y. Hsu et al.|CHEST Journal|2021Cited by 40